| Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
glucose-6-phosphate dehydrogenase | 0.424 | 0.846 | 0.97 |
|
group | 0.400 | None | 0.875 | 0 | 0 | 1977 | 2019 | ||||||||
|
estrogen receptor 1 | 0.324 | 0.962 | 1.00 |
|
group | 0.400 | None | 0.944 | 0 | 0 | 1980 | 2020 | ||||||||
|
HRas proto-oncogene, GTPase | 0.378 | 0.885 | 8.0E-02 |
|
group | 0.400 | None | 0.955 | 0 | 0 | 1983 | 2019 | ||||||||
|
MYC proto-oncogene, bHLH transcription factor | 0.344 | 0.923 | 1.00 |
|
group | 0.600 | None | 0.979 | 0 | 0 | 1984 | 2020 | ||||||||
|
erb-b2 receptor tyrosine kinase 2 | 0.328 | 0.923 | 6.0E-03 |
|
group | 0.400 | None | 0.969 | 0 | 0 | 1985 | 2020 | ||||||||
|
tumor protein p53 | 0.236 | 0.962 | 0.53 |
|
group | 0.400 | None | 0.966 | 0 | 0 | 1986 | 2020 | ||||||||
|
KRAS proto-oncogene, GTPase | 0.320 | 0.923 | 7.9E-04 |
|
group | 0.600 | None | 0.972 | 0 | 0 | 1987 | 2020 | ||||||||
|
epidermal growth factor receptor | 0.295 | 0.885 | 0.37 |
|
group | 0.400 | None | 0.977 | 0 | 0 | 1987 | 2020 | ||||||||
|
fibroblast growth factor receptor 1 | 0.362 | 0.885 | 1.00 |
|
group | 0.400 | None | 0.984 | 0 | 0 | 1988 | 2020 | ||||||||
|
NRAS proto-oncogene, GTPase | 0.390 | 0.808 | 0.49 |
|
group | 0.400 | None | 1.000 | 0 | 0 | 1988 | 2020 | ||||||||
|
cyclin D1 | 0.344 | 0.923 | 0.89 |
|
group | 0.400 | None | 0.978 | 0 | 0 | 1989 | 2020 | ||||||||
|
von Hippel-Lindau tumor suppressor | 0.443 | 0.846 | 8.0E-02 |
|
group | 0.400 | None | 0.959 | 0 | 0 | 1989 | 2019 | ||||||||
|
MET proto-oncogene, receptor tyrosine kinase | 0.380 | 0.846 | 0.97 |
|
group | 0.400 | None | 0.966 | 0 | 0 | 1991 | 2020 | ||||||||
|
APC regulator of WNT signaling pathway | 0.373 | 0.962 | 1.00 |
|
group | 0.400 | None | 0.945 | 0 | 0 | 1992 | 2020 | ||||||||
|
MDM2 proto-oncogene | 0.362 | 0.846 | 1.00 |
|
group | 0.400 | None | 0.977 | 0 | 0 | 1992 | 2020 | ||||||||
|
erb-b2 receptor tyrosine kinase 3 | 0.448 | 0.808 | 1.7E-15 |
|
group | 0.400 | None | 0.977 | 0 | 0 | 1992 | 2020 | ||||||||
|
colony stimulating factor 1 receptor | 0.448 | 0.808 | 0.13 |
|
group | 0.600 | None | 1.000 | 0 | 0 | 1992 | 2020 | ||||||||
|
ret proto-oncogene | 0.392 | 0.885 | 1.00 |
|
group | 0.400 | None | 0.975 | 0 | 0 | 1992 | 2020 | ||||||||
|
cyclin dependent kinase inhibitor 2C | 0.527 | 0.654 | 0.40 |
|
group | 0.400 | None | 0.818 | 0 | 0 | 1993 | 2018 | ||||||||
|
BRCA1 DNA repair associated | 0.367 | 0.923 | 9.2E-29 |
|
group | 0.600 | None | 0.968 | 0 | 0 | 1993 | 2020 | ||||||||
|
cyclin dependent kinase inhibitor 1A | 0.403 | 0.769 | 1.9E-03 |
|
group | 0.400 | None | 0.987 | 0 | 0 | 1994 | 2019 | ||||||||
|
cyclin dependent kinase inhibitor 2A | 0.300 | 0.885 | 0.39 |
|
group | 0.600 | None | 0.946 | 0 | 0 | 1994 | 2020 | ||||||||
|
catenin beta 1 | 0.303 | 0.885 | 1.00 |
|
group | 0.400 | None | 0.978 | 0 | 0 | 1995 | 2020 | ||||||||
|
cyclin D2 | 0.477 | 0.808 | 0.99 |
|
group | 0.400 | None | 1.000 | 0 | 0 | 1995 | 2019 | ||||||||
|
mechanistic target of rapamycin kinase | 0.343 | 0.885 | 1.00 |
|
group | 0.400 | None | 0.982 | 0 | 0 | 1995 | 2020 |